I don't see any reason anyone to do other than keep buying....$18 to $20 is a good 12 month target
small float...sky is the limit
Data from a late-stage study of CTI BioPharma's drug for the bone marrow disorder myelofibrosis were included in the "late breakers," among the most highlighted datasets of the conference. The medicine, pacritinib, "represents an advance in our field," Dr. Lloyd Damon, a clinical professor in the department of medicine at the University of California San Francisco, said in a presentation Saturday. CTI is partnered with Baxter on the medicine.
I don't think GPRO will go below $50 anytime!
does it matter who owns this JUNK, can only be good to wipe your #$%$ with this stock
Sentiment: Strong Sell